Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT HNSCC Vaccine Combination Immunotherapy
NCT03169764Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Adenoviral Vectors, DNA Vaccines, Peptide-based Cancer Vaccines
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK, ETBX-011, ETBX-021, ETBX-051 in head and neck squamous cell carcinoma (HNSCC), sponsored by ImmunityBio, Inc.. Planned start Dec 2017; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicepthaNKETBX-011ETBX-021ETBX-051
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03169764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169764.